# A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

> **NCT01062620** · PHASE1 · COMPLETED · sponsor: **Axelar AB** · enrollment: 49 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** AXL1717

## Key facts

- **NCT ID:** NCT01062620
- **Lead sponsor:** Axelar AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2011-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062620, "A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01062620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*